LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

LLY

1,030.68

+0.87%↑

JNJ

200.1

+0.41%↑

ABBV

233.97

+0.04%↑

UNH

313.81

-2.05%↓

AZN

89.31

+0.18%↑

Kodu・Aktsiate loetelu・Erasca Inc

Erasca Inc

Suletud

2.85 -0.35

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

2.71

Max

2.88

Põhinäitajad
By Trading Economics
Sissetulek	-2.9M -34M
Kasumimarginaal	-768.16
Töötajad	103
EBITDA	-2.5M -38M

Soovitused
By TipRanks
Soovitused	Osta
12 kuu keskmine prognoos	+55.04% upside

Turustatistika
By TradingEconomics
Turukapital	230M 650M
Eelmine avamishind	3.2
Eelmine sulgemishind	2.85

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

1.39 / 1.44 Toetus ja vastupanu

Erasca Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. nov 2025, 19:25 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- 2nd Update

18. nov 2025, 18:09 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough -- Update

18. nov 2025, 17:39 UTC

Omandamised, ülevõtmised, äriostud

Canada Says Anglo American's Pledges to Secure Teck Resources Deal Not Enough

18. nov 2025, 16:25 UTC

Suurimad hinnamuutused turgudel

Diginex Rises on Deal With Digital Asset Platform Evident

18. nov 2025, 23:56 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

18. nov 2025, 23:39 UTC

Market Talk

Nikkei May Rise on Bargain-Hunting Interest -- Market Talk

18. nov 2025, 22:59 UTC

Market Talk

FireFly Metals Can Build Bigger Operation at Green Bay -- Market Talk

18. nov 2025, 22:08 UTC

Market Talk

Sandfire's Kalkaroo Project Push Adds to Copper M&A Surge -- Market Talk

18. nov 2025, 22:03 UTC

Omandamised, ülevõtmised, äriostud

Meta Defeats FTC's Antitrust Case Alleging Social-Media Monopoly -- 3rd Update

18. nov 2025, 22:03 UTC

Tulu

These Stocks Moved the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. nov 2025, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

18. nov 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. nov 2025, 21:15 UTC

Market Talk

Private High-Grade Credit Market Is Changing, BlackRock Says -- Market Talk

18. nov 2025, 20:46 UTC

Market Talk

U.S. Natural Gas Futures Edge Up on Weather Outlook -- Market Talk

18. nov 2025, 20:13 UTC

Market Talk

Distillate Supply Concerns Pull Crude Futures Higher -- Market Talk

18. nov 2025, 19:48 UTC

Market Talk

Gold and Silver Turn Lower on Fed Outlook -- Market Talk

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Anheuser-Busch InBev Nears $700 Million Deal for Party Punch Maker BeatBox -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

Anheuser-Busch InBev in Talks to Buy Party Punch Maker BeatBox, Sources Say -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

AB InBev-BeatBox Deal Could Come Together Soon, Sources Say -- WSJ

18. nov 2025, 19:19 UTC

Omandamised, ülevõtmised, äriostud

AB InBev Deal Would Value BeatBox At Around $700M, Sources Say -- WSJ

18. nov 2025, 18:29 UTC

Tulu

These Stocks Are Moving the Most Today: Nvidia, Microsoft, Home Depot, Cloudflare, Energizer, Honeywell, Medtronic, Klarna, and More -- Barrons.com

18. nov 2025, 18:18 UTC

Market Talk

Ethanol Demand Expected to Boost Corn Futures -- Market Talk

18. nov 2025, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

18. nov 2025, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

18. nov 2025, 17:19 UTC

Market Talk

Tulu

Good Weather Was Bad News for Home Depot's 3Q -- Market Talk

18. nov 2025, 17:06 UTC

Tulu

Medtronic Stock Rises After Earnings. What Caught Investors' Attention. -- Barrons.com

18. nov 2025, 16:06 UTC

Omandamised, ülevõtmised, äriostud

Intuit Stock Gains on OpenAI Deal. ChatGPT Is Coming to TurboTax. -- Barrons.com

18. nov 2025, 15:59 UTC

Tulu

Home Depot Cuts Outlook as Home Improvement Slowdown Continues -- Update

18. nov 2025, 15:35 UTC

Omandamised, ülevõtmised, äriostud

Eni: Acquisition Adds to Plenitude's Installed-Capacity Targets, Bolsters France Presence

18. nov 2025, 15:35 UTC

Omandamised, ülevõtmised, äriostud

Eni: Portfolio Comprises Capacity of Around 760MW in Operation

Võrdlus sarnastega

Hinnamuutus

Erasca Inc Prognoos

Hinnasiht

By TipRanks

55.04% tõus

12 kuu keskmine prognoos

Keskmine 4 USD 55.04%

Kõrge 6 USD

Madal 1 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Erasca Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

Osta

Hoia

Müü

Põhineb 6 analüütiku instrumendi Erasca Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.39 / 1.44Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.